High-selective HDAC6 inhibitor alleviates bone marrow fibrosis through inhibiting collagen formation and extracellular matrix deposition

Abstract Bone marrow fibrosis (BMF) impairs normal hematopoietic functions in patients. The overactivation of the TGF-β signaling pathway is regarded as one of the offenders causing disease progression. Thus, factors capable of regulating TGF-β secretion hold great potential in reversing fibrotic di...

Full description

Saved in:
Bibliographic Details
Main Authors: Chiao-Hsu Ke, Mao-En Huang, Hsin-Yi Wu, Chao-Wu Yu, Shuei-Liong Lin, Shau-Ping Lin, Shu-Han Yu, Chih-Hung Huang, Chen-Si Lin
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-08384-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849237810112888832
author Chiao-Hsu Ke
Mao-En Huang
Hsin-Yi Wu
Chao-Wu Yu
Shuei-Liong Lin
Shau-Ping Lin
Shu-Han Yu
Chih-Hung Huang
Chen-Si Lin
author_facet Chiao-Hsu Ke
Mao-En Huang
Hsin-Yi Wu
Chao-Wu Yu
Shuei-Liong Lin
Shau-Ping Lin
Shu-Han Yu
Chih-Hung Huang
Chen-Si Lin
author_sort Chiao-Hsu Ke
collection DOAJ
description Abstract Bone marrow fibrosis (BMF) impairs normal hematopoietic functions in patients. The overactivation of the TGF-β signaling pathway is regarded as one of the offenders causing disease progression. Thus, factors capable of regulating TGF-β secretion hold great potential in reversing fibrotic diseases. One such factor is histone deacetylase inhibitors (HDACis), which can modulate the expression of TGF-β. Our previous study successfully synthesized a selective HDAC6 inhibitor, J22352, for pulmonary fibrosis; however, the treatment efficacies on BMF remain unclear. Therefore, in this study, we treated bone marrow-derived myofibroblasts with J22352. The results showed that J22352 significantly reduced cell viability, induced apoptosis, and inhibited extracellular matrix (ECM) accumulation. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis was employed to disclose potential mechanisms, identifying 334 differentially expressed proteins (DEPs). The DEPs were involved in cell apoptosis, programmed cell death, ECM deposition, and collagen formation. These results suggest that J22352 efficiently alleviated BMF by inducing cell apoptosis and inhibiting ECM deposition. This study introduces a novel selective HDAC6 inhibitor as a potential option for slowing down the progression of BMF. We aim to provide a promising selective HDACi for clinical medicine through a detailed analysis of its mechanisms and efficacy, offering new prospects in the field.
format Article
id doaj-art-f09a9fbc3a014332b89e02e3d0b608b5
institution Kabale University
issn 2045-2322
language English
publishDate 2025-08-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-f09a9fbc3a014332b89e02e3d0b608b52025-08-20T04:01:51ZengNature PortfolioScientific Reports2045-23222025-08-0115111410.1038/s41598-025-08384-6High-selective HDAC6 inhibitor alleviates bone marrow fibrosis through inhibiting collagen formation and extracellular matrix depositionChiao-Hsu Ke0Mao-En Huang1Hsin-Yi Wu2Chao-Wu Yu3Shuei-Liong Lin4Shau-Ping Lin5Shu-Han Yu6Chih-Hung Huang7Chen-Si Lin8Department of Veterinary Medicine, School of Veterinary Medicine, National Taiwan UniversityDepartment of Veterinary Medicine, School of Veterinary Medicine, National Taiwan UniversityInstrumentation Center, National Taiwan UniversitySchool of Pharmacy, College of Medicine, National Taiwan UniversityGraduate Institute of Physiology, College of Medicine, National Taiwan UniversityAgricultural Biotechnology Research Center, Academia SinicaInstitute of Biotechnology, National Taiwan UniversityDepartment of Chemical Engineering and Biotechnology, Institute of Chemical Engineering, National Taipei University of TechnologyDepartment of Veterinary Medicine, School of Veterinary Medicine, National Taiwan UniversityAbstract Bone marrow fibrosis (BMF) impairs normal hematopoietic functions in patients. The overactivation of the TGF-β signaling pathway is regarded as one of the offenders causing disease progression. Thus, factors capable of regulating TGF-β secretion hold great potential in reversing fibrotic diseases. One such factor is histone deacetylase inhibitors (HDACis), which can modulate the expression of TGF-β. Our previous study successfully synthesized a selective HDAC6 inhibitor, J22352, for pulmonary fibrosis; however, the treatment efficacies on BMF remain unclear. Therefore, in this study, we treated bone marrow-derived myofibroblasts with J22352. The results showed that J22352 significantly reduced cell viability, induced apoptosis, and inhibited extracellular matrix (ECM) accumulation. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis was employed to disclose potential mechanisms, identifying 334 differentially expressed proteins (DEPs). The DEPs were involved in cell apoptosis, programmed cell death, ECM deposition, and collagen formation. These results suggest that J22352 efficiently alleviated BMF by inducing cell apoptosis and inhibiting ECM deposition. This study introduces a novel selective HDAC6 inhibitor as a potential option for slowing down the progression of BMF. We aim to provide a promising selective HDACi for clinical medicine through a detailed analysis of its mechanisms and efficacy, offering new prospects in the field.https://doi.org/10.1038/s41598-025-08384-6Bone marrow fibrosisHistone deacetylase inhibitorTransforming growth factor-β (TGF-β)Organ fibrosis
spellingShingle Chiao-Hsu Ke
Mao-En Huang
Hsin-Yi Wu
Chao-Wu Yu
Shuei-Liong Lin
Shau-Ping Lin
Shu-Han Yu
Chih-Hung Huang
Chen-Si Lin
High-selective HDAC6 inhibitor alleviates bone marrow fibrosis through inhibiting collagen formation and extracellular matrix deposition
Scientific Reports
Bone marrow fibrosis
Histone deacetylase inhibitor
Transforming growth factor-β (TGF-β)
Organ fibrosis
title High-selective HDAC6 inhibitor alleviates bone marrow fibrosis through inhibiting collagen formation and extracellular matrix deposition
title_full High-selective HDAC6 inhibitor alleviates bone marrow fibrosis through inhibiting collagen formation and extracellular matrix deposition
title_fullStr High-selective HDAC6 inhibitor alleviates bone marrow fibrosis through inhibiting collagen formation and extracellular matrix deposition
title_full_unstemmed High-selective HDAC6 inhibitor alleviates bone marrow fibrosis through inhibiting collagen formation and extracellular matrix deposition
title_short High-selective HDAC6 inhibitor alleviates bone marrow fibrosis through inhibiting collagen formation and extracellular matrix deposition
title_sort high selective hdac6 inhibitor alleviates bone marrow fibrosis through inhibiting collagen formation and extracellular matrix deposition
topic Bone marrow fibrosis
Histone deacetylase inhibitor
Transforming growth factor-β (TGF-β)
Organ fibrosis
url https://doi.org/10.1038/s41598-025-08384-6
work_keys_str_mv AT chiaohsuke highselectivehdac6inhibitoralleviatesbonemarrowfibrosisthroughinhibitingcollagenformationandextracellularmatrixdeposition
AT maoenhuang highselectivehdac6inhibitoralleviatesbonemarrowfibrosisthroughinhibitingcollagenformationandextracellularmatrixdeposition
AT hsinyiwu highselectivehdac6inhibitoralleviatesbonemarrowfibrosisthroughinhibitingcollagenformationandextracellularmatrixdeposition
AT chaowuyu highselectivehdac6inhibitoralleviatesbonemarrowfibrosisthroughinhibitingcollagenformationandextracellularmatrixdeposition
AT shueilionglin highselectivehdac6inhibitoralleviatesbonemarrowfibrosisthroughinhibitingcollagenformationandextracellularmatrixdeposition
AT shaupinglin highselectivehdac6inhibitoralleviatesbonemarrowfibrosisthroughinhibitingcollagenformationandextracellularmatrixdeposition
AT shuhanyu highselectivehdac6inhibitoralleviatesbonemarrowfibrosisthroughinhibitingcollagenformationandextracellularmatrixdeposition
AT chihhunghuang highselectivehdac6inhibitoralleviatesbonemarrowfibrosisthroughinhibitingcollagenformationandextracellularmatrixdeposition
AT chensilin highselectivehdac6inhibitoralleviatesbonemarrowfibrosisthroughinhibitingcollagenformationandextracellularmatrixdeposition